GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » EV-to-EBIT

Research Alliance II (Research Alliance II) EV-to-EBIT : -241.24 (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Research Alliance II's Enterprise Value is $193.96 Mil. Research Alliance II's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.80 Mil. Therefore, Research Alliance II's EV-to-EBIT for today is -241.24.

The historical rank and industry rank for Research Alliance II's EV-to-EBIT or its related term are showing as below:

RACB's EV-to-EBIT is not ranked *
in the Diversified Financial Services industry.
Industry Median: 9.53
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Research Alliance II's Enterprise Value for the quarter that ended in Sep. 2022 was $188.20 Mil. Research Alliance II's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.80 Mil. Research Alliance II's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -0.43%.


Research Alliance II EV-to-EBIT Historical Data

The historical data trend for Research Alliance II's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Research Alliance II EV-to-EBIT Chart

Research Alliance II Annual Data
Trend Dec20 Dec21
EV-to-EBIT
- -398.29

Research Alliance II Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBIT Get a 7-Day Free Trial -600.12 -398.29 -251.01 -240.58 -234.08

Competitive Comparison of Research Alliance II's EV-to-EBIT

For the Shell Companies subindustry, Research Alliance II's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Research Alliance II's EV-to-EBIT Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Research Alliance II's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Research Alliance II's EV-to-EBIT falls into.



Research Alliance II EV-to-EBIT Calculation

Research Alliance II's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=193.955/-0.804
=-241.24

Research Alliance II's current Enterprise Value is $193.96 Mil.
Research Alliance II's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Research Alliance II  (NAS:RACB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Research Alliance II's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=-0.804/188.201295
=-0.43 %

Research Alliance II's Enterprise Value for the quarter that ended in Sep. 2022 was $188.20 Mil.
Research Alliance II's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Research Alliance II EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Research Alliance II's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Research Alliance II (Research Alliance II) Business Description

Traded in Other Exchanges
N/A
Address
3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108
Research Alliance Corp II is a blank check company.
Executives
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky director, officer: Chief Executive Officer 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman director C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett director C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond director, officer: Chief Investment Officer 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc 10 percent owner 200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron director, 10 percent owner, officer: Chief Financial Officer C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience director C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire 11-28-2022